927181-96-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Ethoxyindole is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its properties make it instrumental in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Production:
7-Ethoxyindole is utilized as a chemical intermediate in the production of agrochemicals. Its role in this industry is crucial for the synthesis of compounds that can be used in the development of pesticides and other agricultural products.
Used in Specialty Chemicals Industry:
7-Ethoxyindole is employed as a chemical intermediate for the production of specialty chemicals. Its unique reactivity and structural features are harnessed to create compounds with specific applications in various industries, such as fragrances, dyes, and other specialty chemical products.

InChI:InChI=1/C10H11NO/c1-2-12-9-5-3-4-8-6-7-11-10(8)9/h3-7,11H,2H2,1H3

Upstream product

• 2380-84-9 7-Indolol 
• 75-03-6 ethyl iodide 

Downstream Products

• 566200-31-5 7-ethoxy-1H-indole-3-carbaldehyde 
• 179819-92-2 3-(2-aminopropyl)-7-ethoxyindole 

Relevant academic research and scientific papers

Discovery of a novel and potent human and rat β3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl] -1H-indol-7-yloxy]acetic acid

In search for potent and selective β3-adrenergic receptor (β3-AR) agonists as potential drugs for the treatment of type II diabetes and obesity, a novel series of 1-(3-chlorophenyl)-2-aminoethanol derivatives were prepared and evaluated for their biological activity at human β1-, β2-, and β3-ARs and rat β3-AR expressed in Chinese hamster ovary (CHO) cells. Replacement of the right-hand side (RHS, benzene ring) in the 'first generation' β3-AR agonists BRL 37344 and CL 316243 with a 1H-indole ring gave compound 31 with unique pharmacological properties among β3-AR agonists. Initial in vitro assays showed that 31 possesses modest rat and human β3-ARs agonistic activity. Introduction of various substituent into the indole nucleus of 31 afforded a number of compounds with good β3-ARs agonistic activity. In particular, 90 having a carboxylic acid functionality at the 7-position of the indole nucleus showed the most potent human β3-AR agonistic activity. Finally, optical resolution of 90 led to the identification of the most promising compound, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H- indol-7-yloxy]acetic acid (96, AJ-9677). This compound exhibited potent human β3-AR agonistic activity (EC50 = 0.062 nM, IA = 116%) with 210- and 103-fold selectivity over human β2-AR and β1-AR, respectively. Compound 96 also exhibited potent rat β3-AR agonistic activity (EC50 = 0.016 nM, IA = 110%). Moreover, repeated oral administration of 96 inhibited body weight gain and significantly decreased glucose, insulin, free fatty acid, and triglyceride concentrations in plasma in KK-Ay/Ta mice. On the basis of this pharmacological profile, 96 entered clinical development as a drug for the treatment of type II diabetes and obesity.